Here's Why You Should Add Inogen Stock to Your Portfolio Now

Inogen (INGN) is positioned for growth, driven by strong demand for portable oxygen concentrators (POCs), with the POC market projected to reach $22.63 billion by 2029, and strategic collaborations with Jiangsu Yuyue and Yuwell to expand its product portfolio and market presence, particularly in China. First-quarter 2025 revenues increased 5.5% year-over-year, with domestic and international business-to-business sales up 29.9% and 22.9% respectively; however, the company faces challenges from seasonality, increased advertising headwinds, and foreign exchange volatility, which negatively impacted international sales by 160 basis points in Q1 2025.

Analysis

Inogen (INGN), a provider of portable oxygen concentrators (POCs) with a market capitalization of $205.9 million, is positioned for growth within the robust POC market, which is projected to expand at an 8.5% CAGR to $22.63 billion by 2029. The company's first-quarter 2025 financial results demonstrated positive momentum, with a 5.5% year-over-year increase in quarterly revenues, significantly driven by a 29.9% rise in domestic business-to-business sales and a 22.9% increase in international business-to-business sales, while adjusted gross margin improved by 20 basis points to 47.9%. Key strategic initiatives include the recent FDA clearance for its Simeoxin product in the U.S. and collaborations with Jiangsu Yuyue Medical Equipment & Supply Co. and Yuwell, aimed at broadening its product portfolio, enhancing innovation, and accelerating entry into the Chinese market. Despite these strengths, a Zacks Rank #2 (Buy) rating, a projected 7.2% earnings growth for 2025, and an attractive price-to-sales ratio of 0.6x compared to the industry's 2.6x, Inogen's stock has underperformed, declining 21.4% year-to-date. The company faces challenges including typical seasonal softness in its direct-to-consumer channel, anticipated advertising headwinds, and foreign exchange volatility, which negatively impacted Q1 2025 international sales by 160 basis points. Nonetheless, there is a positive trend in analyst estimates, with the Zacks Consensus Estimate for its 2025 loss per share narrowing by 9.4% in the past 30 days.

Key Decisions for Investors

• Investors could consider the current depressed share price, down 21.4% year-to-date, as a potential entry point, given Inogen's strong Q1 business-to-business growth, attractive price-to-sales ratio of 0.6x, and the expanding portable oxygen concentrator market.
• Carefully monitor Inogen's ability to mitigate direct-to-consumer sales pressures and navigate foreign exchange headwinds in upcoming quarters, as these are critical factors for achieving the projected 7.2% earnings growth in 2025.
• Evaluate the execution of strategic partnerships with Jiangsu Yuyue and Yuwell, and the market adoption of new products like Simeoxin and the Rove 4, as these are key catalysts for future revenue generation and market share expansion.